SPECIFIC  DYSPEPTIC SYMPTOMS ARE ASSOCIATED WITH POOR RESPONSE TO THERAPY IN PATIENTS WITH GASTROESOPHAGEAL REFLUX  DISEASE by D’Alessandro, A et al.
Original Article
Specific dyspeptic symptoms are associated
with poor response to therapy in patients
with gastroesophageal reflux disease
A D’Alessandro, FP Zito, M Pesce, P Andreozzi, E Efficie,
M Cargiolli, F Maione, GD De Palma, R Cuomo and G Sarnelli
Abstract
Introduction: In patients with gastroesophageal reflux disease (GORD), co-existence of functional dyspepsia (FD) is known to
be associated with poor response to proton pump inhibitors (PPIs), but the contribution of specific dyspepsia symptoms has
not yet been systematically investigated.
Objective: We aimed to characterize the impact of dyspepsia symptoms on response to PPIs in patients with GORD.
Methods: The enrolled subjects were consecutive patients with a diagnosis of GORD. All patients underwent a 24 hour pH–
impedance test, while on PPI therapy. Patients were divided into two groups, refractory and responders, according to the
persistence of GORD symptoms. A standardized questionnaire for FD was also administered to assess presence of dyspepsia
symptoms.
Results: In the subgroup of refractory patients FD was more prevalent than in responders, with post-prandial fullness,
nausea, vomiting, early satiation and epigastric pain being significantly prevalent in refractory GORD patients. In the
multivariate analysis only early satiation and vomiting were significantly associated with poor response to PPIs.
Conclusion: Co-existence of FD is associated with refractory GORD. We showed that only early satiation and vomiting are risk
factors for poor response to therapy with PPIs. Our findings suggest that symptoms of early satiation and vomiting would
help to identify the subset of PPI-refractory GORD patients.
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Introduction
Gastro-oesophageal reﬂux disease (GORD) is one of
the most prevalent upper gastrointestinal (GI) dis-
orders, and is characterized by the recurrence of heart-
burn and/or regurgitation.1 Acid suppression with
proton pump inhibitors (PPIs) is the mainstay of ther-
apy for GORD, with a good rate of response.2
However, about 30% of treated patients are referred
for persistent GORD symptoms while on PPI therapy.3
The failure of acid suppression represents a challenge
for the gastroenterologist; in fact, to date, there is no
standardized treatment for refractory GORD, and the
underlying mechanisms remain unclear.4
Several mechanisms have been hypothesized to
explain refractory GORD, in particular reﬂux of non-
acid gastroduodenal contents, defective mucosal barrier
function, hypersensitivity to normal acid exposure,
poor peristalsis or delayed gastric emptying and func-
tional heartburn/chest pain syndrome.5 Some of these
mechanisms seem to be also involved in functional dys-
pepsia (FD),6–8 and this common pathophysiological
background may explain the high degree of overlap
between these diseases. Depending on the study, the
rate of overlap ranges from 20% to up to 50%, and
the role of dyspeptic symptoms in response to PPIs is
still unclear.9–11
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Tack et al. showed that epigastric pain is the more
frequent dyspeptic symptom reported by PPI-responder
GORD patients.10 This ﬁnding likely reﬂects the use
of acid suppressive therapy in the subtype of FD
with ‘epigastric pain syndrome’ (EPS).12–14 However,
PPI therapy is less eﬃcacious in dyspeptic patients suf-
fering from post-prandial distress syndrome (PDS),
characterized by early satiation and post-prandial
fullness.12–15
In a recent review, FD has been found to be more
prevalent in GORD patients who had the worst
response to PPIs, likely suggesting that coexisting dys-
pepsia is a risk factor for refractory GORD.3 However,
the impact of speciﬁc dyspepsia symptoms in the subset
of refractory GORD patients has not yet been system-
atically reported.
The aim of our study is thus to evaluate the impact
of speciﬁc dyspeptic symptoms on response to PPIs in
patients with GORD.
Material and methods
Subjects
For this study, 132 consecutive patients with typical
GORD symptoms (heartburn and acid regurgitation)
were screened. Patients underwent careful history
taking, clinical examination, routine biochemistry,
upper GI endoscopy, and oesophageal manometry
test. During endoscopy, biopsies were taken from the
antrum and corpus for routine histology and to check
for the presence of Helicobacter pylori. Inclusion cri-
teria were the presence of heartburn and/or regurgita-
tion lasting for more than 6 months and occurring at
least three times weekly. Exclusion criteria were the
presence of gastric atrophy, H. pylori infection, major
abdominal surgery, peptic ulcer, severe oesophageal
motility disorders, eosinophilic oesophagitis, Barrett’s
oesophagus, underlying psychiatric illness, and use of
non-steroidal anti-inﬂammatory drugs (NSAIDs). All
subjects received and signed an informed consent
and the University Ethics Committee approved all
procedures.
Symptom questionnaires
At baseline, all patients were given a modiﬁed six-item
questionnaire assessing presence of typical and atypical
GORD symptoms (heartburn, regurgitation, dyspha-
gia, food regurgitation, odynophagia and chest pain).
The severity (0–3; 0¼ absent, 1¼mild, 2¼ relevant and
3¼ severe, interfering with daily activities) of all
GORD symptoms was recorded using a previously vali-
dated questionnaire.11
All patients were then put on double-dose PPI ther-
apy (Pantoprazole 20mg b.i.d.) for 12 weeks. At the
end of the therapy, the GORD symptoms questionnaire
was again administered to all subjects, and patients
with persistent heartburn and/or regurgitation, at
least once a week, were considered as having refractory
GORD.3
Chronic dyspeptic symptoms were deﬁned as the
presence of epigastric pain/burning, nausea, vomiting,
early satiation, post-prandial fullness, belching and
bloating for the last 3 months with onset of symptoms
at least 6 months before clinical evaluation; symptoms’
severity was also evaluated using previously validated
questionnaire (0–3; interfering with daily life).11
Ambulatory pH–impedance monitoring
Patients underwent ambulatory multichannel intralum-
inal impedance–pH monitoring while on PPI therapy.
The system included a portable data logger and a cath-
eter with two antimony pH electrodes at 5 cm above
and 10 cm below the lower oesophageal sphincter
(LOS) and six impedance electrodes at 3, 5, 7, 9, 15
and 17 cm above the LOS (ZepHr Recorder, Sandhill
Scientiﬁc, Colorado, USA). Data stored on a compact-
ﬂash card were analysed using speciﬁc diagnostic soft-
ware (BioVIEW, Sandhill Scientiﬁc). Recorded
pH–impedance data were used to determine the
number of reﬂux events, oesophageal acid exposure,
intragastric pH, percentage of time that gastric pH
was less than 4 and to classify the type of reﬂuxate
(acid reﬂux: pH< 4, weakly acid reﬂux: 4<pH< 7
and weakly alkaline reﬂux: pH> 7). Symptom associ-
ation probability (SAP) and symptom index (SI) were
also computed. Intragastric pH was evaluated in all
subjects, and only patients with intragastric pH> 4
for more than 75% of the time were included.2,3
Data analysis
Age, body mass index (BMI) and all pH–impedance
parameters were compared by Student’s t-test; the over-
all prevalence of dyspepsia and of speciﬁc dyspeptic
symptoms was analysed by Fisher exact test. Stepwise
multiple logistic regression analysis was used to identify
the association between the risk of refractory GORD
and the presence of dyspeptic symptoms and demo-
graphic features. P-values of 0.05 and 0.01 were
chosen as cut-oﬀ points to respectively enter and exit
the stepwise procedure. Odds ratios with 95% conﬁ-
dence interval (CI) were computed. Diﬀerences were
considered to be signiﬁcant at the 5% level. All data
are given as mean SD. Statistical evaluations were
performed using specialized software (SPSS, IBM
Corporation).
2 United European Gastroenterology Journal 0(0)
 at Univ Studi Napoli Federico II on August 3, 2016ueg.sagepub.comDownloaded from 
Results
For this study, 132 consecutive GORD patients were
screened; among them eight patients were excluded
(four for peptic ulcer and concomitant H. pylori infec-
tion, three for concurrent use of NSAIDs, of whom one
had also a diagnosis of Barrett’s oesophagus, and one
for oesophageal motility disorder) and four patients
refused to participate in the study. Twenty-two patients
had previous evidence of H. pylori infection that was
successfully eradicated.
In total, 120 patients (67 females, age 56 15 years,
GORD symptoms’ score: 3.2 1.8) were included.
After the pH–impedance monitoring, 20 patients were
excluded because of poor acid suppression.
Demographic features and pH–impedance
parameters do not affect PPIs response in
GORD patients
We identiﬁed 67 responders (38 females, age 54 12
years; GORD symptoms score: 0.5 0.6) and 33 refrac-
tory patients (21 females, age 58 15, GORD symp-
toms score: 2.3 1.3). No signiﬁcant diﬀerences in
terms of sex, age or BMI were found between these
two groups. Data are shown in Table 1. The analysis
of the pH–impedance parameters are shown in Table 2
and in Supplementary Information, and revealed no
signiﬁcant diﬀerences between the two groups.
Functional dyspepsia is prevalent in
refractory GORD patients
Overall, dyspepsia symptoms were signiﬁcantly more
prevalent in the subgroup of refractory GORD patients
than in responders (64 vs. 37%, p< 0.01). Also, the sum
of intensity score of all dyspeptic symptoms was higher
in refractory patients than in responders (mean score:
7.4 vs. 3.3, p< 0.01). Although when dyspepsia symp-
toms were grouped in EPS and PDS dyspepsia sub-
types, the prevalence was similar in refractory and
responder GORD patients (EPS: 3 vs. 8.9%; PDS: 9
vs. 8.9%; p all NS), the refractory GORD patients
showed a signiﬁcantly higher prevalence of overlap
between EPS and PDS than responders (54.5 vs.
17.9%; p< 0.01).
Specific dyspeptic symptoms influence PPIs
response in a different way
The analysis of speciﬁc dyspeptic symptoms revealed
that post-prandial fullness, nausea, vomiting, early sati-
ation and epigastric pain were all signiﬁcantly more
frequent in refractory than in responder patients with
GORD (all p< 0.05, Figure 1(a)), while the prevalence
of bloating and belching was similar (30 vs. 24 and 33
vs. 20%, respectively; p all NS). These results were also
conﬁrmed when only severe symptoms were evaluated
(i.e. severity score> 2; Figure 1(b)).
Figure 2 summarizes the risk contribution of each
dyspepsia symptom on PPI response, but when data
were computed in a multivariate analysis only early
satiation and vomiting were conﬁrmed to be risk fac-
tors for PPI refractoriness (OR 4, CI 1–14, p¼ 0.039
and OR 7, CI 1.4–34, p¼ 0.017; Figure 3). Also, the co-
existence of several dyspeptic symptoms was associated
with the worst clinical outcome in GORD patients
(p< 0.05); however, speciﬁcally excluding early sati-
ation from this analysis, no signiﬁcant diﬀerences in
terms of PPI response were found between patients
with one or more dyspeptic symptoms.
Analysis of pH-II parameters in patients with
prevalent early satiation and vomiting
In order to verify the role of early satiation and vomit-
ing in the genesis of heartburn and/or regurgitation we
evaluated pH-II parameters in patients referring for
vomiting and early satiation. In the table 3 it is reported
that no signiﬁcant diﬀerences in terms of oesophageal
acid exposure and number of acid or non-acid reﬂuxes
were found.
Table 1. Characteristics of patients
Prevalence Female Age (years) BMI (kg/m2) p
Responder 67% 64% 54 12 27 4 ns
Refractory 33% 57% 58 15 28 5 ns
Table 2. pH–impedance parameters in responder and refractory GERD patients
Acid exposure Total reflux Acid reflux Weakly acid reflux SAP SI
Responder 0.66 1.85 60.5 35.5 8.5 11.2 49.3 30 12.5 6 21.2 12.5
Refractory 0.67 0.60 50.0 29.5 7.7 15.5 39.2 24.5 10.6 5.2 23 15
P ns ns ns ns ns ns
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Discussion
PPIs are widely used across the world, due to the high
prevalence of acid-related GI disorders, PPI eﬀective-
ness and safety.15,16 They are the most potent inhibitors
of acid secretion available, and represent the mainstay
of therapy for GORD with a good rate of response.2
However, according to literature, 30% of patients refer
for persistent heartburn and regurgitation despite the
therapy.3 As expected, the prevalence of refractory
GORD in our population was 33%, conﬁrming the
current literature data.3
Recent ﬁndings have shown that FD is a risk factor
for poor response to acid suppression and, given the
high prevalence of both the diseases, it is well known
that these entities frequently overlap.1,3,9–12 In keeping
with previous studies,9–12 in our population of patients
with GORD the prevalence of FD was at least 50%. As
expected, the occurrence of FD symptoms was signiﬁ-
cantly higher in the refractory group than in respon-
ders. This evidence was also sustained by the higher
intensity of FD symptoms in patients with persistent
typical GORD symptoms. Our data thus conﬁrm the
high degree of overlap and, in agreement with Sifrim
and Zerbib, support the role of FD in refractory
GORD.3
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Figure 1. A – Prevalence of post-prandial fullness, nausea, vomiting, early satiation and epigastric pain was significantly higher in
refractory (black) than in responder (white) GORD patients; no significant differences were found in prevalence of belching and bloating.
B – The same data were found when only moderate–severe symptoms were considered (intensity score> 2).
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Figure 2. Epigastric pain, early satiation, nausea, vomiting, epigastric burning and post-prandial fullness were associated with a
significantly lower response to PPIs, while bloating and belching did not interfere with PPI response in GORD patients.
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Figure 3. Multivariate analysis revealed that among all the dyspeptic
symptoms, only vomiting and early satiation were risk factors signifi-
cantly associated with poor response to PPIs in GORD patients.
4 United European Gastroenterology Journal 0(0)
 at Univ Studi Napoli Federico II on August 3, 2016ueg.sagepub.comDownloaded from 
When meal-related dyspeptic symptoms were ana-
lysed they were found to be more prevalent in refrac-
tory GORD patients, but when the analysis was run
considering the subgroups of PDS and EPS no signiﬁ-
cant diﬀerence in prevalence was found between refrac-
tory and responder groups of GORD patients.
However, this result likely reﬂects the contribution of
patients overlapping epigastric pain and post-prandial
distress syndromes; in fact, the prevalence of overlap
between EPS and PDS was signiﬁcantly higher in
refractory GORD patients. These data highlight the
role of speciﬁc symptoms rather than dyspepsia sub-
types in response to PPIs.
In keeping with this, a systematic analysis revealed
that post-prandial fullness, nausea, vomiting, early sati-
ation and epigastric pain were more signiﬁcantly preva-
lent and they were associated with a higher risk of
refractory GORD. However, from the multivariate
analysis only early satiation and vomiting were con-
ﬁrmed to be risk factors for poor response to PPI
therapy.
Moreover, according to our data, the number of dys-
peptic symptoms also plays a role in the outcome for
GORD patients; in fact, here we report that the co-
existence of several dyspeptic symptoms was associated
with a worse clinical outcome. However, we observed
that among patients suﬀering from several FD symp-
toms, the prevalence of refractory GORD was signiﬁ-
cantly higher only in the cluster of patients with early
satiation. This result supports the hypothesis that the
type, rather than the co-existence of multiple dyspepsia
symptoms is likely to aﬀect the outcome in patients
with GORD. Our results conﬁrm that these diseases
inﬂuence each other, and suggest the presence of one
or more pathophysiological backgrounds likely asso-
ciated with both refractory GORD and speciﬁc FD
symptoms.
In fact, although acid reﬂux is considered the main
cause of GORD symptoms, the mechanisms involved in
the genesis of heartburn and regurgitation, especially in
refractory patients, seem to be more complicated and
are still unclear.5 Mechanical stimulation of
oesophagus, mucosal hypersensitivity and impairment
of centrally acting pain modulators are postulated to
underlie heartburn in patients with persistent symptoms
despite acid suppression.4 Similarly, an altered percep-
tion of mechanical and chemical stimuli seems to play
an important role also in the pathophysiology of
FD.11,16–18 Moreover, motility disorders commonly
associated with FD, such as delayed gastric emptying
and impaired accommodation, may facilitate both acid
and non-acid oesophageal reﬂux, reducing the rate of
response to PPIs,19–22 although in this study we did not
observe any signiﬁcant diﬀerence in terms of number of
reﬂuxes in patients suﬀering from early satiation and
vomiting compared with other GORD patients.
In conclusion, our study conﬁrms the close relation-
ship between FD and GORD, highlighting that speciﬁc
dyspeptic symptoms inﬂuence the rate of response to
PPIs. These ﬁndings may guide further pathophysio-
logical studies and help clinicians in the management
of refractory GORD.
Supplementary information
Prevalence of normal and abnormal pH–impedance
monitoring was similar in responder and refractory
GORD patients (p¼ 0.35; Fisher’s exact test).
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Responder (%) Refractory (%)
Normal pH–impedance 46 26
Abnormal pH–impedance 21 7
Total 67 33
Table 3. pH–impedance parameters in patients suffering from early satiation (ES) or vomiting (VO).
Acid exposure Total reflux Acid reflux Weakly acid reflux
Gaseous
acid reflux
Gaseous weakly
alkaline reflux
All pts without ES or VO 0.8 3 57.4 30.7 7.5 11.5 48 27 0.6 1.6 0.43 1.4
ES 0.8 2.9 57.7 30.7 7 11 48.9 27.4 0.7 1.6 0.64 1.3
p* ns ns ns ns ns ns
VO 0.4 0.5 44.3 27.1 11.8 19.8 47.1 20.3 1.4 3.7 2.1 1.6
p* ns ns ns ns ns ns
*p versus patients without ES and VO
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